retatrutide mechanism glp-1 gip glucagon triple agonist review 2024 2025 Retatrutide, a GIP, and receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA 🎙️ NEW EPISODE: Retatrutide—The Triple

US$ 23.56

★★★★★ 5.0 (15 reviews)

US$ 20.93

★★★★★ 5.0 (18 reviews)

US$ 24.33

★★★★★ 4.8 (19 reviews)

US$ 28.58

★★★★★ 5.0 (14 reviews)

US$ 21.90

★★★★★ 4.8 (21 reviews)

US$ 25.47

★★★★★ 4.1 (8 reviews)

US$ 29.65

★★★★★ 4.7 (24 reviews)

US$ 24.49

★★★★★ 4.3 (18 reviews)

US$ 25.35

★★★★★ 4.6 (19 reviews)

US$ 28.85

★★★★★ 4.4 (12 reviews)

US$ 28.04

★★★★★ 4.0 (22 reviews)

US$ 23.05

★★★★★ 4.5 (18 reviews)

US$ 29.41

★★★★★ 4.9 (15 reviews)

US$ 23.12

★★★★★ 4.9 (19 reviews)

US$ 25.77

★★★★★ 4.3 (16 reviews)

US$ 26.48

★★★★★ 4.1 (10 reviews)

US$ 27.25

★★★★★ 4.6 (9 reviews)

US$ 25.99

★★★★★ 5.0 (8 reviews)

US$ 25.76

★★★★★ 4.3 (21 reviews)

US$ 28.40

★★★★★ 4.2 (5 reviews)